[Gonadotropi adenoma linking labeled somatostatin analogs. Lack of relationship with therapeutic effect].
Somatotropin- and thyrotropin-secreting adenomas are well known for positive uptake of radio-labeled octreotide in vivo, this fact is not so well assessed for gonadotropin-secreting adenomas (GSA). We report one case of positive somatostatin receptor scintigraphy in a woman suffering from histologically proven GSA. This 63 year old patient has been suffering for two years of akinetic syndrome when the outcome of diplopia led to the discovery of a large hypophyseal tumor spreading till V3 floor and in left cavernous sinus by resonance magnetic imaging (RMI). Clinical examination showed anterior hypopituitarism and bitemporal hemianopsia. Biologically, blood gonadotropins were decreased more on LH (0.6 UI/l, N > 15) than on FSH (10 UI/l; N > 20). A lack of response of gonadotropins to LHRH with low blood estradiol concentration (< 10 pg/ml) was noticed. Basal blood measurement of alpha subunit was at 0.17 microgram/l (N = 0.10-1.6) and increased at 0.39 microgram/l after stimulation by LHRH. Although in low range of normal values, other hypophyseal hormones were normal except prolactinemia (45 mg/L; N < 20), however stimulated by TRH and related to dopaminergic deconnection; Indium 111 labeled octreotide scintigraphy showed an over uptake of the tumor. Three month treatment by octreotide (100 micrograms x 3/day subcutaneously) did not allow to decrease significantly FSH concentration or to reduce the tumoral mass. Incomplete removal of the tumor was performed by transphenoidal route. Immunohistochemical analysis revealed positive immunostaining for alpha subunit and FSH beta on numerous cells while the labeling was slightly less strong for LH beta. These data evoked a GSA. This case record depicts the possibility of detection of GSA by somatostatin receptor imaging. However a positive result does not preclude of somatostatin analog therapeutic efficiency.
Evrard
A
A
Service d'Endocrinologie et Métabolismes, Lille.
Vantyghem
M C
MC
Huglo
D
D
Hober
C
C
Marchandise
X
X
Mazzuca
M
M
Lefebvre
J
J
D000236:Adenoma / Q000097:blood / Q000000981:diagnostic imaging* / Q000378:metabolism* / Q000628:therapy; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D006065:Gonadotropins, Pituitary / Q000378:metabolism*; D006801:Humans; D008875:Middle Aged; D015282:Octreotide / Q000627:therapeutic use; D010907:Pituitary Hormones / Q000097:blood; D010911:Pituitary Neoplasms / Q000097:blood / Q000000981:diagnostic imaging* / Q000378:metabolism* / Q000628:therapy; D011184:Postoperative Period; D011877:Radionuclide Imaging
D018931:Antineoplastic Agents, Hormonal; D006065:Gonadotropins, Pituitary; D010907:Pituitary Hormones; D015282:Octreotide
Adénome gonadotrope fixant un analogue de la somatostatine marquée. Absence de corrélation avec l'efficacité thérapeutique.